Management Teamabout : management team
 Dr. Aladar A. Szalay, who formed Genelux Corporation in 2001, is internationally recognized as a leader in the monitoring of gene regulation and in whole cell and live organism imaging using light-emitting proteins or protein fusions. Based on his long-time research interest and recent discoveries, the company is utilizing live microorganisms to locate (diagnose) and eliminate (therapy) human tumor xenografts. In addition, to guide the research and development program of Genelux Corporation, Dr. Szalay currently holds a university professor position at the Rudolf Virchow Center of Experimental Biomedicine, School of Medicine, and also at the Biocenter at the University of Würzburg in Würzburg, Germany, where he directs a research program with graduate students and post-doctoral fellows on whole body imaging. He was recently appointed to a full professor position in the Department of Radiation Oncology at the Rebecca and John Moores Comprehensive Cancer Center, at the University of California, San Diego. His previous academic appointments were: professor of molecular genetics and microbiology and founding director of the Center for Molecular Biology and Gene Therapy at Loma Linda University School of Medicine in Loma Linda, California; Canadian Pacific Endowed Chair Professor of biotechnology and molecular genetics at the University of Alberta in Edmonton, Canada; associate research scientist of molecular genetics at the Boyce Thompson Institute and adjunct professor at Cornell University in Ithaca, New York; and Gosney fellow at the California Institute of Technology in Pasadena, California. He has published over 160 scientific papers and holds over 50 issued patents and patent applications. Dr. Szalay is the recipient of the Wilhelm Exner Award (Medal for Excellence in Science) from Austria and the Alexander von Humboldt Prize from Germany, among others. He has functioned as an advisor for numerous research foundations, served on the Board of Directors and the Scientific Advisory Board for several biomedical start-up companies and was invited to serve as a genetic engineering, gene transfer and therapy expert for several multi-national pharmaceutical and diagnostic equipment manufacturing companies in the US, Europe and Japan.
 Dr. Staib holds a PhD in biochemistry and human genetics and a master’s degree in biochemistry, microbiology and animal physiology from the University of Würzburg. Her PhD thesis was honored as the best in the University of Würzburg in 1998. In 2007 she completed her habilitation in Virology at the Medical Faculty of the Technical University of Munich in Germany. Dr. Staib joined Genelux Corporation in 2006. As head of product development, she manages virus manufacturing, product optimization, quality control and analytical characterization. She collaborates with the scientific research team for preclinical product testing and with the clinical trials team for preparation of regulatory documents. Prior to joining Genelux Corporation, she was head of a research group at the Institute of Virology at the Technical University of Munich in Germany, where she gained eight years of experience carrying out leading research in the field of orthopox- and vaccinia viruses, with an emphasis on vaccine development and optimization. Dr. Staib has (co-)authored a variety of original peer-reviewed scientific publications, as well as reviews, book chapters and patent applications.
 Dr. Albert Röder joined Genelux Corporation in 2004 after retiring from Roche Applied Science as Head of Global R&D and Marketing Support. In February of that year, he was elected to the Board of Directors of Genelux Corporation. His distinguished 33-year career in the pharmaceutical industry included several operative and leadership positions in research and development, manufacturing, marketing, strategy and business development within international cross-functional teams. Before joining Roche, he worked for Boehringer Mannheim Biochemical, where he rose to Head of Research in Enzymology/Proteinchemistry and Chemistry, then to Head of the Global Product Supply Unit. He holds a PhD in organic chemistry from the University of Tübingen in Germany.
 Dr. Kevin T. Murphy joined Genelux Corporation in 2008 as Chief Strategy Officer. Dr. Murphy is a Board-Certified Radiation Oncologist on faculty at the University of California San Diego in the Department of Radiation Oncology in the Rebecca and John Moores NCI-designated Comprehensive Cancer Center. After spending time in private practice, he was recruited to UCSD in 2005, initially serving as Medical Director in the Department of Radiation Oncology and more recently as Director of Strategy and Business Development and Chief of the Stereotactic Radiosurgery and Pediatric Oncology Programs. His clinical and research interests focus on novel radiation technologies and their application in the treatment of children and tumors of the central nervous system. A graduate of the University of Notre Dame, Dr. Murphy received his M.D. and residency training at the University of Chicago. During his final year in Chicago, his research focused on the integration of radiation therapy and viral gene therapy in the treatment of cancer. Dr. Murphy will divide his time between Genelux Corporation and UCSD.
Ulrike Szalay joined Genelux in January, 2007. Having spent several years in international trade consulting, she specializes in international regulatory, business and government affairs, corporate policy, media relations and trade affairs. Prior to starting her own business, she handled international government relations for McDonald’s Corporation on a wide variety of trade and other policy matters directly affecting the company’s business interests. Ms. Szalay also has co-authored several health care and public opinion articles and a book during her tenure with Harvard University’s Public Opinion Project. She holds a Masters in Public Policy from Harvard University’s John F. Kennedy School of Government. She has served as co-chair of the Women in Government Relations International Trade Task Force and a member of the Organization of Women in International Trade.
Copyright © 2007 Genelux |
Disclaimer
|